Company intelligence / Profile preview
ImmunoMet Therapeutics
Houston, Texas, United Statesimmunomet.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ImmunoMet’s lead molecule, lixumistat (IM156), is an orally bioavailable small molecule PC1 inhibitor that targets oxidative phosphorylation. It has completed Phase 1 studies demonstrating good tolerability and target inhibition. In a Phase 1b trial in advanced pancreatic cancer, lixumistat combined with gemcitabine/nab-paclitaxel showed promising safety at the recommended phase 2 dose of 400 mg QD. The compound has received Orphan Drug Designation for pancreatic cancer and glioblastoma multiforme. Additional programs are at earlier stages or preclinical development.[3][4][7]
- Therapeutic areas
- OtherOncologyImmunology
- Modalities
- Small molecules (notably biguanides)[1][4][7]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
No major pharmaceutical partnerships disclosed; collaborations with academic centers such as MD Anderson Cancer Center noted via clinical trials leadership.[7]Investors include HanAll Biopharma and Incon Co., Ltd., among others.[10]
Beyond the preview
Go deeper on ImmunoMet Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmunoMet Therapeutics.